Börsipäev 18. veebruar
Postitusi kokku 10
AloV

<p>Cody Willard:</p><p><a class="MainHeadline" id="entryId10209652" name="entryId10209652"><b><font color="#000066" size="4">Coincidental Resistance</font></b></a><br /><span class="Time"><font size="1">2/18/05 8:40 AM ET</font></span></p><p><span class="StoryText">The Nasdaq failed almost exactly to the digit at its 50 day moving average. Coincidence?</span></p><p>Here's something you won't read just about anywhere else - yes. I think it's a coincidence that the Nasdaq turned nasty at that <a href="http://www.thestreet.com/p/dps/td/tradingdiary2.html#entryId10209499"><u><font color="#000066">so-called</font></u></a> (so-called so-called?)resistance. Think about it this way: If the Nazz had busted through the 50 day moving average, we'd all have read about how it had "cleared the hurdle". If it'd stopped and bounced right around 50 day moving average, we'd have heard how it was "bumping into resistance". But since it hit the 50 day moving average and immediately sold off - well, now we read about how it "failed at resistance".</p><p>As a matter of fact, one can <i>always</i> find new ways of technically analyzing the markets to "explain" the action. That's why all those billions of dollars are spent on software programs that draw 20 or 50 (or whatever other day) simple or moving (or some other variation) day averages on this, that or the other index. Or to draw those lines from one place to another on some important stock that's supposedly a "tell" for the rest of the market.</p><p>You have to wonder though - does the cut-throat world of capitalism really reward such activity?</p><p>At any rate, the Nasdaq failed at its 50 day moving average. Did I mention that already?</p><p>The close yesterday was particularly ugly as the downward momentum escalated into the close. Beyond a few outperformers such as <b>Apple</b> and <b>F5</b> , tech has been hard hit this year. Small-cap, high-beta names like <b>Charter</b> and <b>Finisar</b> have just been trashed and thrashed for weeks on end. There's been an obvious rotation to high-priced momentum names and out of low-priced beta names. That rotation will end when it ends, if you know what I mean.</p><p>In the meantime, I'm still waiting for a better set up to get terribly aggressive either on the long or the short side outside of some individual stock set ups that I like, including <b>MRV Communications</b> and Tekelec .</p><p>Here's a good way <a href="http://www.frenzy.com/~jester/racecar.html"><u><font color="#000066">to start off this Friday</font></u></a> after a long, hard week. Back with more soon.</p><p><i>Net long AAPL, FFIV, FNSR, MRVC, TKLC</i></p><p><em>Gary B. Smith:</em></p><p><em><img alt="" src="/images/files/24210.gif" border="0" /></em></p>

arkok

Gapping Up <br /><br /> Gapping up on strong earnings/guidance: CRM +10.7%, NVDA +8.5%, AEIS +10.3% (also CIBC upgrade), AKAM +10%, CRYP +8.6%, TOPT +7.6%, VCLK +7.1%, MDRX +6.5%, PCLN +5.3%.... Other News: TIVO +10.8% (reaches 3 mln subs), PRM +8.6% (co's about.com to be sold to NYT), PKZ +6.6% (CIBC says co could have nearly $10/sh in cash by year-end), MAY +5.5% (FD resumes its takeover talks with May - WSJ), GRU +5.5%, SIGM +5% (started with an Outperform at Baird; tgt $20), MCIP +4.3% (Qwest plans revised offer for MCIP), MRK +3.8% (may return Vioxx to market), SINA +3.7%, FWHT +3.5% (London's The Sun newspaper chooses co's espotting.com over Google for paid listings - Forbes), TZOO +2.9%, SNIC +2.7% (added to JP Morgan's Focus List; tgt $21)... Under $3: SYNC +12.3% (posts largest non-GAAP profit in over 5 yrs). <br /><br />Gapping Down <br /><br /> Gapping down on disappointing earnings/guidance: NTGR -9.6%, ADIC -9.3% (also Bear Stearns downgrade), RAE -7%, ISNS -7%, INTU -1.9%, Other News: NTEC -7.6% (prices offering at $4/sh), DSCO -5.2% (stock offering), LGF -3.7% (announces convertible offering), CTIC -2.5% (profit taking from 12% move yesterday), BBY -1.1% (Goldman downgrade). <br /><br />

jim

Kuigi ise realmoneyt eriti ei jälgi, on tore näha, et Cody Willard TKLC suhtes samal arvamusel on.

kristjan.lepik

UBS tõstis NVDA reitingut Neutrali pealt Buy peale.

kristjan.lepik

CRM - mitte nii võimsalt kui PNRA, kuid squeeze siiski.

jim

PFE Pfizer: Celebrex increases heart risk, FDA panel votes - Bloomberg

jim

PFE Pfizer: Celebrex should still be marketed in U.S. -- DJ<br /><br />Päris suur kott tõmmati shortidele pähe.

jim

PFE Pfizer: Celebrex should still be marketed in U.S. -- DJ<br /><br />Päris suur kott tõmmati shortidele pähe.

ragulka

mis siis teie turunägemus on.. mul iseenesest lootus, et nadaq lõpetab täna kasvõi väikeses plussis. muidu on vist küll kurvad lood...